ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC)

CAPS Rating: 2 out of 5

Recs

2
Player Avatar zzlangerhans (99.69) Submitted: 10/22/2011 2:12:51 AM : Outperform Start Price: $1.44 IMUC Score: +22.66

Hard to believe I'm green-thumbing a company who pays for promotion by VFC. That's kind of like paying Gaddafi to manage your public relations. And sometimes I can't remember the difference between ImmunoCellular and Northwest. But I'm seeing ImmunoCellular close to the 2011 low despite a raging bull market, and no likely short term negative catalysts with the phase II trial of ICT-07 in the midst of enrollment. So my first pitch is a green, but unless I get swirled don't expect it to stay for long.

Featured Broker Partners


Advertisement